Gout therapeutics: New drugs for an old disease

The Lancet

Volumn 377, Issue 9760, 2011, Pages 165-177

  Burns, Christopher M ^a   Wortmann, Robert L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CANAKINUMAB; FEBUXOSTAT; PEGLOTICASE; PLACEBO; RDEA 594; RDEA 806; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG METABOLISM; GOUT; HEADACHE; HUMAN; LICENSING; LIVER FUNCTION TEST; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROLITHIASIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT;

EID: 79151481493     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60665-4     Document Type: Review

References (99)

1. DJ McCarty Jr, JL Hollander Identification of urate crystals in gouty synovial fluid Ann Intern Med 54 1961 452 460
2. KL Wallace, AA Riedel, N Joseph-Ridge, R Wortmann Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population J Rheumatol 31 2004 1582 1587
3. KG Saag, H Choi Epidemiology, risk factors, and lifestyle modifications for gout Arthritis Res Ther 8 2006 S2
4. E Roddy, W Zhang, M Doherty The changing epidemiology of gout Nat Clin Pract Rheumatol 3 2007 443 449
5. L Annemans, E Spaepen, M Gaskin Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005 Ann Rheum Dis 67 2008 960 966
6. LR Harrold, K Saag, RA Yood Validity of gout diagnoses in administrative data Arthritis Rheum 57 2007 103 108
7. P Richette, T Bardin Gout Lancet 375 2010 318 328
8. K Okamoto, BT Eger, T Nishino, S Kondo, EF Pai, T Nishino An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition J Biol Chem 278 2003 1848 1855
9. MA Becker, J Kisicki, R Khosravan Febuxostat (TMX-67), a novel, nonpurine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers Nucleosides Nucleotides Nucleic Acids 23 2004 1111 1116
10. Y Takano, K Hase-Aoki, H Horiuchi Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase Life Sci 76 2005 1835 1847
11. K Komoriya, S Hoshide, K Takeda Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia Nucleosides Nucleotides Nucleic Acids 23 2004 1119 1122
12. R Khosravan, BA Grabowski, JT Wu, N Joseph-Ridge, L Vernillet Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects Clin Pharmacokinet 45 2006 821 841
13. MD Mayer, R Khosravan, L Vernillet, JT Wu, N Joseph-Ridge, DJ Mulford Pharmacokinetics and pharmacodynamics of febuxostat, a new selective nonpurine inhibitor of xanthine oxidase, in subjects with renal impairment Am J Ther 12 2005 22 34
14. MA Becker, HR Schumacher Jr, RL Wortmann Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout Arthritis Rheum 52 2005 916 923
15. MA Becker, HR Schumacher Jr, RL Wortmann Febuxostat compared with allopurinol in patients with hyperuricemia and gout N Engl J Med 353 2005 2450 2461
16. HR Schumacher, MA Becker, RL Wortmann Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel group trial Arthritis Care Res 59 2008 1540 1548
17. M Becker, HR Schumacher Jr, L Espinoza A phase 3 randomized, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout Arthritis Rheum 58 2008 S4029 S4030
18. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
19. HR Schumacher Jr, MA Becker, E Lloyd, PA MacDonald, C Lademacher Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study Rheumatology 48 2009 188 194
20. MA Becker, HR Schumacher, PA MacDonald, L Lloyd, C Lademacher Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout J Rheumatol 36 2009 1273 1282
21. European Medicines Agency CHMP assessment report for Adenuric http://www.emea.europa.eu/humandocs/PDFs/EPAR/adenuric/H-777-en6.pdf 2008 (accessed Feb 1, 2010).
22. R Khosravan, BA Grabowski, MD Mayer, JT Wu, N Joseph-Ridge, L Vernillet The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase J Clin Pharmacol 46 2006 88 102
23. R Khosravan, MD Mayer, JT Wu Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state Arthritis Rheum 52 2005 S102 S103
24. RP Khosravan, KB Erdman, LPP Vernillet Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects Clin Pharmacol Ther 77 2005 P43
25. BA Grabowski, R Khosravan, JT Wu Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat Arthritis Rheum 52 2005 S103 S104
26. R Khosravan, JT Wu, N Joseph-Ridge Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs J Clin Pharmacol 46 2006 855 866
27. M Mukoyoshi, S Nishimura, S Hoshide In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition Xenobiotica 38 2008 496 510
28. MA Becker, HR Schumacher, RL Wortmann Allopurinol intolerant patients treated with febuxostat for 4 years Arthritis Rheum 54 2006 S646
29. XW Wu, CC Lee, DM Muzny, CT Caskey Urate oxidase: primary structure and evolutionary implications Proc Natl Acad Sci USA 86 1989 9412 9416
30. P Laboureur, C Langlois Urate-oxydase d'Aspergillus flavus: I. Obtention, purification, propriétés Bull Soc Chim Biol 50 1968 811 825
31. C-H Pui, MV Relling, F Lascombes Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies Leukemia 11 1997 1813 1816
32. MB Davidson, S Thakkar, JK Hix, ND Bhandarkar, A Wong, MJ Schreiber Pathophysiology, clinical consequences and treatment of tumor lysis syndrome Am J Med 116 2004 546 554
33. P Leplatois, B Le Douarin, G Loison High-level production of a peroxisomal enzyme: Aspergillus flavus uricase accumulates intracellularly and is active in Saccharomyces cerevisiae Gene 122 1992 139 145
34. PM Navolanic, C-H Pui, RA Larson Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002 Leukemia 17 2003 499 514
35. JM de Bont, R Pieters Management of hyperuricemia with rasburicase review Nucleosides Nucleotides Nucleic Acids 23 2004 1431 1440
36. P Richette, T Bardin Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol Nat Clin Pract Rheumatol 2 2006 338 342
37. P Richette, C Briere, V Honene-Claviert, D Loeuille, T Bardin Rasburicase for tophaceous gout not treatable with allopurinol: An exploratory study J Rheumatol 34 2007 1093 1098
38. R Terkeltaub Learning how and when to employ uricase as bridge therapy in refractory gout J Rheumatol 34 2007 1955 1958
39. MR Sherman, MGP Saifer, F Perez-Ruiz PEG-uricase in the management of treatment-resistant gout and hyperuricemia Adv Drug Deliv Rev 60 2008 59 68
40. JS Sundy, NJ Ganson, SJ Kelly Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout Arthritis Rheum 56 2007 1021 1028
41. NJ Ganson, SJ Kelly, E Scarlett, JS Sundy, MS Hershfield Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase Arthritis Res Ther 8 2006 R12
42. JS Sundy, MA Becker, HSB Baraf Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout Arthritis Rheum 58 2008 2882 2891
43. HS Baraf, AK Matsumoto, AN Maroli, RW Waltrip Resolution of gouty tophi after twelve weeks of pegloticase treatment Arthritis Rheum 58 2008 3632 3634
44. JS Sundy, HS Baraf, MA Becker Efficacy and safety of intravenous pegloticase (PGL) in treatment failure gout (TFG): results from GOUT1 and GOUT2 Ann Rheum Dis 68 2009 318
45. HS Baraf, MA Becker, NL Edwards Tophus response to pegloticase (PGL) therapy: pooled results from GOUT1 and GOUT2, PGL phase 3 randomized, double blind, placebo-controlled trials Arthritis Rheum 58 2008 S176
46. NL Edwards, HS Baraf, MA Becker Improvement in health-related quality of life (HRQL) and disability index in treatment failure gout (TFG) after pegloticase (PGL) therapy: pooled results from GOUT1 and GOUT2, phase 3, randomized, double blind, placebo (PBO)-controlled trials Arthritis Rheum 58 2008 S178
47. MA Becker, EL Treadwell, HS Baraf Immunoreactivity and clinical response to pegloticase (PGL): pooled data from GOUT1 and GOUT2, PGL phase 3 randomized, double blind, placebo-controlled trials Arthritis Rheum 58 2008 S880
48. D Wright, JS Sundy, T Rosario-Jansen Routine serum uric acid (SUA) monitoring predicts antibody-mediated loss of response and infusion reaction risk during pegloticase therapy Arthritis Rheum 60 2009 S413
49. US Food and Drug Administration Briefing Document for the Arthritis Advisory Committee Meeting http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetings Materials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM165714.pdf (accessed Feb 15, 2010).
50. JS Sundy, HS Baraf, SR Gutierrez-Urena Chronic use of pegloticase: study and efficacy update Arthritis Rheum 60 2009 S417
51. JB Wyngaarden, WN Kelley Disposition of uric acid in primary gout JB Wyngaarden WN Kelley Gout and hyperuricemia 1976 Grune & Stratton New York 149 157
52. PA Simkin New standards for uric acid excretion: evidence for an inducible transporter Arthritis Care Res 49 2003 735 736
53. A Enomoto, H Kimura, A Chairoungdu Molecular identification of a renal urate anion exchanger that regulates blood urate levels Nature 417 2002 447 452
54. H Endou, N Anzai Urate transport across the apical membrane of renal proximal tubules Nucleosides Nucleotides Nucleic Acids 27 2008 578 584
55. Y Hagos, D Stein, B Ugele, G Burckhardt, A Bahn Human renal organic anion transporter 4 operates as an asymmetric urate transporter J Am Soc Nephrol 18 2007 430 439
56. R Augustin, MO Carayannopoulos, LO Dowd, JE Phay, JF Moley, KH Moley Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking J Biol Chem 279 2004 16229 16236
57. V Vitart, I Rudan, C Hayward SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout Nat Genet 40 2008 437 442
58. N Anzai, K Ichida, P Jutabha Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans J Biol Chem 283 2008 26834 26838
59. MJ Caulfield, PB Munroe, D O'Neill SLC2A9 is a high-capacity urate transporter in humans PLoS Med 5 2008 e197
60. N Dalbeth, T Merriman Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout Rheumatology 48 2009 222 226
61. L Yeh, V Hingorani, K Manhard Safety and uric acid lowering effect in humans following multiple doses of RDEA806, a novel prodrug for the potential treatment of hyperuricemia Ann Rheum Dis 67 2008 248
62. L Yeh, I Tamai, R Hamatake Mode of action of RDEA594 as a uric acid lowering agent in humans following multiple doses of its prodrug, RDEA806 Ann Rheum Dis 67 2008 249
63. L-T Yeh, Z Shen, B Kerr Safety, pharmacokinetics, and serum uric acid lowering effect of RDEA594, a novel uricosuric agent, in healthy volunteers Ann Rheum Dis 68 2009 320
64. L-T Yeh, Z Shen, B Kerr RDEA594, a potent URAT1 inhibitor without affecting other important renal transporters OAT1 and OAT3 Ann Rheum Dis 68 2009 320
65. X Yang, R Dick, V Borges Evaluation of drug-drug interaction potential between RDEA594, allopurinol and febuxostat in preclinical species Arthritis Rheum 60 2009 S412 S413
66. B Lasko, B Sheedy, V Hingorani RDEA594, a novel uricosuric agent, significantly reduced serum urate levels and was well tolerated in a phase 2a pilot study in hyperuricemic gout patients Arthritis Rheum 60 2009 S413 S414
67. E Goldfarb, CJ Smythe Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout Arthritis Rheum 9 2007 414 423
68. F Perez-Ruiz, M Calabozo, JI Pijoan, AM Herrero-Beites, A Ruibal Effect of urate-lowering therapy on the velocity of size of reduction of tophi in chronic gout Arthritis Rheum 47 2002 356 360
69. R Liu-Bryan, P Scott, A Sydlaske, DM Rose, R Terkeltaub Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation Arthritis Rheum 52 2005 2936 2946
70. F Martinon, V Petrilli, A Mayor, A Tardivel, J Tschopp Gout-associated uric acid crystal activate the NALP3 inflammasome Nature 440 2006 237 241
71. FS Di Giovine, SE Malawista, G Nuki, GW Duff Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL-1 J Immunol 138 1987 3213 3218
72. CJ Chen, Y Shi, A Hearn MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals J Clin Invest 116 2006 2262 2271
73. CT Mayer, JW Tobias, JP Menetski, HR Schumacher Jr, F Pessler Dynamics of transcription regulation of urate crystal inflammation in a synovium-like tissue Arthritis Rheum 60 2009 S729
74. A So, T De Smedt, S Revaz, J Tschopp A pilot study of IL-1 inhibition by anakinra in acute gout Arthritis Res Ther 9 2007 R28
75. R Terkeltaub, JS Sundy, HR Schumacher The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study Ann Rheum Dis 68 2009 1613 1617
76. HR Schumacher Jr, JS Sundy, R Terkeltaub Placebo-controlled study of rilonacept for gout flare prophylaxis during initiation of urate-lowering therapy Arthritis Rheum 60 2009 S410
77. A So, M De Meulemeester, T Shamim Canakinumab (ACZ885) vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients refractory to or contraindicated to NSAIDs and/or colchicine Arthritis Rheum 60 2009 LB4
78. BN Cronstein, R Terkeltaub The inflammatory process of gout and its treatment Arthritis Res Ther 8 2006 S3
79. R Terkeltaub Novel therapies for treatment of gout and hyperuricemia Arthritis Res Ther 11 2009 236
80. E Krishnan, D Lienesch, CK Kwoh Gout in Ambulatory Care Settings in the United States J Rheumatol 35 2008 498 501
81. RT Keenan, RA Lehman, WR O'Brien, DB Crittenden, KH Lee, MH Pillinger Gout management in primary care vs. rheumatology: evidence for suboptimal treatment Arthritis Rheum 60 2009 S415
82. W Zhang, M Doherty, E Pascual EULAR evidence based recommendations for gout. Part I: diagnosis: report of a task force of the Standing committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 65 2006 1301 1311
83. W Zhang, M Doherty, T Bardin EULAR evidence bases recommendations for gout. Part II: management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 65 2006 1312 1324
84. L Stamp, K Sharples, P Gow, B Raill The optimal use of allopurinol: an audit of allopurinol use in South Auckland Aust N Z J Med 30 2000 567 572
85. N Schlesinger, HR Schumacher Jr Gout: can management be improved? Curr Opin Rheumatol 13 2001 240 244
86. CA Sarawate, KK Brewer, W Yang Gout medication treatment patterns and adherence to standards of care from a managed care perspective Mayo Clin Proc 81 2006 925 934
87. CA Sarawate, PA Patel, HR Schumacher Jr, W Yang, KK Brewer, AW Bakst Serum urate levels and gout flares: analysis from managed care data J Clin Rheum 12 2006 61 65
88. RL Wortmann, LM Ryan Management of crystal-induced arthropathies RL Wortmann HR Schumacher Jr MA Becker LM Ryan Crystal induced arthropathies: gout, pseudogout and apatite-associated syndromes 2006 Taylor & Francis New York
89. MA Becker, S Chohan We can make gout management more successful now Curr Opin Rheumatol 20 2008 167 172
90. JS Sundy Gout management: let's get it right this time Arthritis Care Res 59 2008 1535 1537
91. F Perez-Ruiz, A Alonso-Ruiz, M Calabozo, A Herrero-Beites, G Garcia-Erauskin, E Ruiz-Lucea Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenic approach to the therapy of chronic primary gout Ann Rheum Dis 57 1998 545 549
92. N Dalbeth, S Kumar, L Stamp, P Gow Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout J Rheumatol 33 2006 1646 1650
93. F Perez-Ruiz, F Lioté Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Care & Research 57 2007 1324 1328
94. KR Hande, RM Noone, WJ Stone Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency Am J Med 76 1984 47 56
95. N Dalbeth, L Stamp Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events Semin Dial 20 2007 391 395
96. F Perez-Ruiz, M Calabozo, AM Herrero-Beites, G García-Erauskin, JI Pijoan Improvement in renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts Nephron 86 2000 287 291
97. YP Siu, KT Leung, MK Tong, TH Kwan Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid Am J Kidney Dis 47 2006 51 59
98. MS Silverberg, R Mallela, AJ Lesse, MR Bonner, AN Baer, C Li Allopurinol hypersensitivity reaction: a case-control study of the role of renal dosing Arthritis Rheum 60 2009 S414
99. L Stamp, JL O'Donnell, M Zhang, C Frampton, M Barclay, PT Chapman Increasing allopurinol dose above the recommended range is effective and safe in chronic gout, including in those with renal impairment - a pilot study Arthritis Rheum 60 2009 S729